Skip to main content
Fig. 2 | BMC Rheumatology

Fig. 2

From: Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis

Fig. 2

Lupus-like phenotype in NZB/W mice is ameliorated by lanraplenib treatment. a Experimental study design to test the efficacy of lanraplenib. Lanraplenib was formulated in chow at the indicated percentages. Proteinuria was measured every week starting at week 28. b Kaplan-Meier curve showing the percentage of surviving mice at each time point; n = 15 mice per group at week 28. c Percentage of mice with proteinuria (≥ 100 mg/dL) at each time point. Treatment groups are stylized as in b. d Blood urea nitrogen measurement at week 40. Each point represents an individual mouse at the time of sacrifice. Mean ± SEM are indicated for each treatment group. Statistics were calculated comparing the vehicle control group to each other group using a Kruskal-Wallis test. e Mean body weight of mice in each group ± SEM. Treatment groups are stylized as in b. Food consumption was measured daily; no differences in food consumption were observed across any treatment groups. * Indicates P < 0.05. *** indicates P < 0.0005. Indicates blood draws for dsDNA Ab measurement. Indicates blood draws for PK measurement

Back to article page